Provider Network Models
Expert articles and analysis related to provider network models.
AI Summary — Last 30 Days
CMS is broadening provider-network and payment-model leverage across both Medicare and Medicaid: the 2027 Ambulatory Specialty Model participant list signals continued movement of specialty practices into accountable, episode- or condition-oriented payment, while ACCESS outcome-aligned billing guidance pushes chronic care vendors and provider partners toward measurable longitudinal outcomes rather than fee-for-service activity. At the same time, the Trump administration’s GENEROUS Medicaid drug-pricing model—now with all states applying—creates a parallel affordability lever that could reshape payer-provider pharmacy strategy, formulary alignment, and total-cost-of-care performance in Medicaid risk arrangements (ACC on specialty model participants; [AHA on GENEROUS Model participation](https://news.google.com/rss/articles/CBMizgFBVV95cUxOOWhnN0wxZTRDYWJNSFg1Um0zS2pFMl9JZG5ZYmF6TGZsNjlIUEx6T0tfV29hck5KTm1zb1U4dHhXWDNvaUJMbjNGTmU1WTdmaWwyWjViVng3QUVJdlBCRVNsQ1lZbXhVSmpzSW51cUFBMF9PbUE5U1d3Wm16QmhPQzRqTV
Related Articles
STAT+: How Trump’s latest pharma deals may undermine efforts to rein in drug costs
Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no price cuts in Medicare.
Administration announces a new set of drug pricing agreements
Administration announces a new set of drug pricing agreements American Hospital Association
Three takeaways from Trump's latest drug pricing event
President Donald Trump announced voluntary drug pricing deals with nine new companies on Monday, for the first time veering outside of the original crop of companies that he singled out in letters las...
Mid-cap biotechs join Trump’s latest round of drug pricing deals
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies.
Midsized Biotechs Strike MFN Drug Pricing Deals
Trump strikes Medicaid drug price deals with pharma firms
Trump strikes Medicaid drug price deals with pharma firms Modern Healthcare
Trump announces nine new MFN drug pricing deals
Nine new companies have announced voluntary drug pricing deals with the White House, looking to avoid industry tariffs and inclusion in two CMS pilot programs under review that are thought to be poten...
Trump strikes nine more deals with drugmakers to lower prices
President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.
STAT+: 5 burning questions on Trump’s latest deals with drugmakers
Here are some of the key questions about the agreements the Trump administration has reached with drugmakers on pricing.
AHA Pushes Back Against Sen. Cassidy’s 340B Proposals
AHA Pushes Back Against Sen. Cassidy’s 340B Proposals HealthLeaders Media